Logotype for Co-Diagnostics Inc

Co-Diagnostics (CODX) Proxy filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Co-Diagnostics Inc

Proxy filing summary

19 Oct, 2026

Executive summary

  • Court-ordered special meeting follows two 2026 annual-meeting sessions that lacked the then-required majority quorum; the court set a 33⅓% quorum for this meeting and reconvened sessions, without changing approval thresholds.

  • Nine proposals cover director elections, equity-plan shares, say-on-pay, auditor ratification, future meeting quorum, warrant and note share issuances, reverse splits, and adjournment; the Board unanimously recommends FOR each.

Voting matters and shareholder proposals

  • Five directors are nominated for one-year terms through the 2027 annual meeting: Dwight Egan, Eugene Durenard, Richard Serbin, James Nelson, and Edward Murphy; election is by plurality.

  • Proposal 2 seeks 2,000,000 additional 2025 Plan shares, increasing the reserve from 223,333 to 2,223,333; 123,333 shares remained available as of the record date.

  • Proposal 3 is a non-binding advisory vote on 2025 named executive compensation; the Compensation Committee will consider the result in future pay decisions.

  • Proposal 4 asks shareholders to ratify Tanner LLC for FY2026; Proposal 5 would set a one-third quorum for future annual and special meetings while leaving substantive voting thresholds unchanged.

  • Proposals 6–9 seek approval of up to 3,404,724 warrant shares at $1.56, note-related share issuance, reverse splits totaling up to 1-for-750 within 12 months, and meeting adjournment; proposals 2–9 require a majority of votes cast.

Board of directors and corporate governance

  • The five-member Board has four independent non-employee directors; it met 11 times in 2025, and each director attended more than 75% of applicable Board and committee meetings.

  • Four standing committees cover audit, compensation, corporate governance, and nominations; Eugene Durenard chairs audit and is designated the audit committee financial expert.

  • Compensation, governance, and nominating committee matters were handled in Board meetings as needed in 2025; none of those committees met separately that year.

  • Board nominee review considers experience, education, employment history, skills, participation, geography, and diversity factors; there is no formal diversity policy.

  • Dwight Egan petitioned for a court-ordered shareholder meeting and reduced quorum; the Board consented, and the court order stated it did not involve allegations of wrongdoing.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Co-Diagnostics